文献速递免疫规划卫生政策与健康促进

抗体作为COVID-19疫苗保护相关物的证据

Evidence for antibody as a protective correlate for COVID-19 vaccines.
PubMed 文献 · Vaccine · 2021-05-24

为加速COVID-19疫苗开发,研究者评估了7种疫苗的效力与体外中和及结合抗体的关系。校准至恢复期血清滴度后,中和滴度与效力呈强相关(ρ=0.79),结合抗体滴度与效力亦强相关(ρ=0.93),支持以免疫后抗体滴度作为保护相关物基础。

要点

  • 中和抗体滴度与疫苗效力强相关(ρ=0.79)。
  • 结合抗体滴度与疫苗效力强相关(ρ=0.93)。
  • 支持以免疫后抗体滴度建立保护相关物。

核心结论

  • 免疫后中和与结合抗体滴度与COVID-19疫苗效力强相关,支持其作为保护相关物的基础。

研究设计与样本

  • 评估7种已有足够数据的疫苗,分析效力与体外中和及结合抗体的关系,并校准至各研究报告的人恢复期血清滴度。

主要发现

  • 中和滴度与效力相关系数ρ=0.79。
  • 结合抗体滴度与效力相关系数ρ=0.93。
  • 研究人群地理多样、受不同感染压力和流行变异株影响,且使用不同终点、检测方法、恢复期血清盘和生产平台。

关键数值与推荐

  • 中和滴度与效力相关系数ρ=0.79。
  • 结合抗体滴度与效力相关系数ρ=0.93。

临床怎么用

  • 可考虑将免疫后抗体滴度作为建立COVID-19疫苗保护相关物的依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A correlate of protection (CoP) is urgently needed to expedite development of additional COVID-19 vaccines to meet unprecedented global demand. To assess whether antibody titers may reasonably predict efficacy and serve as the basis of a CoP, we evaluated the relationship between efficacy and in vitro neutralizing and binding antibodies of 7 vaccines for which sufficient data have been generated. Once calibrated to titers of human convalescent sera reported in each study, a robust correlation was seen between neutralizing titer and efficacy (ρ = 0.79) and binding antibody titer and efficacy (ρ = 0.93), despite geographically diverse study populations subject to different forces of infection and circulating variants, and use of different endpoints, assays, convalescent sera panels and manufacturing platforms. Together with evidence from natural history studies and animal models, these results support the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021. PMID: 34210573. doi:10.1016/j.vaccine.2021.05.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。